This page shows the latest Relistor news and features for those working in and with pharma, biotech and healthcare.
Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands. ... Xifaxan and Relistor are integral to our gastrointestinal franchise which remains a core asset for future growth potential in the hands of Valeant.".
Valeant and Salix are also expecting to benefit from the launch of a new oral form of its injectable Relistor (methylnaltrexone bromide) product for cancer pain.
Nevertheless, in the latter half of last year Salix introduced three new products - Ruconest for hereditary angioedema, Relistor (methylnaltrexone bromide) subcutaneous injection for chronic non-cancer pain and Uceris (budesonide) rectal
Concern about the safety of the PAMORA class - which also includes Cubist Pharma's Entereg (alvimopan) and Salix' Relistor (methylnaltrexone) - emerged after one of phase III trials conducted with Entereg showed
Salix also brings a number of smaller GI products including Apriso (mesalamine) for ulcerative colitis (UC) and Relistor (methylnaltrexone bromide) for opioid-induced constipation, while Santarus provides recently-launched Uceris (budesonide)
Platform. 614. Xencor/Amgen. XmAb5871, mAb for auto-immune diseases. Preclinical. 500. Allergan/Valeant (Biovail) ###. Aczone for acne vulgaris. Marketed. 450. Progenics/Salix. Relistor for opioid induced constipation.
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
On the other hand, Salix boasts a 22 product portfolio including the prescription brands Uceris (ulcerative colitis), Relistor (constipation), and Apriso (ulcerative colitis) and a strong near-term pipeline, however the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...